These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 17216598

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro.
    Lu Y, Wang J, Xu Y, Koch AE, Cai Z, Chen X, Galson DL, Taichman RS, Zhang J.
    Mol Cancer Res; 2008 Apr; 6(4):546-54. PubMed ID: 18344492
    [Abstract] [Full Text] [Related]

  • 3. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
    Vaday GG, Peehl DM, Kadam PA, Lawrence DM.
    Prostate; 2006 Feb 01; 66(2):124-34. PubMed ID: 16161154
    [Abstract] [Full Text] [Related]

  • 4. Expression and functional role of CCR9 in prostate cancer cell migration and invasion.
    Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW.
    Clin Cancer Res; 2004 Dec 15; 10(24):8743-50. PubMed ID: 15623660
    [Abstract] [Full Text] [Related]

  • 5. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
    Chen Q, Watson JT, Marengo SR, Decker KS, Coleman I, Nelson PS, Sikes RA.
    Cancer Lett; 2006 Dec 08; 244(2):274-88. PubMed ID: 16500022
    [Abstract] [Full Text] [Related]

  • 6. The significance of LMO2 expression in the progression of prostate cancer.
    Ma S, Guan XY, Beh PS, Wong KY, Chan YP, Yuen HF, Vielkind J, Chan KW.
    J Pathol; 2007 Feb 08; 211(3):278-85. PubMed ID: 17167821
    [Abstract] [Full Text] [Related]

  • 7. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
    Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, Spera G, Gnessi L.
    J Urol; 2006 Jun 08; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
    [Abstract] [Full Text] [Related]

  • 8. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
    Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V.
    Anticancer Res; 2003 Jun 08; 23(5A):3825-35. PubMed ID: 14666684
    [Abstract] [Full Text] [Related]

  • 9. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.
    Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P, Michel MS.
    Anticancer Res; 2005 Jun 08; 25(1A):183-91. PubMed ID: 15816537
    [Abstract] [Full Text] [Related]

  • 10. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
    Rehman I, Azzouzi AR, Cross SS, Deloulme JC, Catto JW, Wylde N, Larre S, Champigneuille J, Hamdy FC.
    Hum Pathol; 2004 Nov 08; 35(11):1385-91. PubMed ID: 15668896
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
    Kobayashi T, Shimizu Y, Terada N, Yamasaki T, Nakamura E, Toda Y, Nishiyama H, Kamoto T, Ogawa O, Inoue T.
    Prostate; 2010 Jun 01; 70(8):866-74. PubMed ID: 20127734
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA.
    Banerjee AG, Liu J, Yuan Y, Gopalakrishnan VK, Johansson SL, Dinda AK, Gupta NP, Trevino L, Vishwanatha JK.
    Mol Cancer; 2003 Oct 08; 2():34. PubMed ID: 14613585
    [Abstract] [Full Text] [Related]

  • 15. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer.
    Koike H, Sekine Y, Kamiya M, Nakazato H, Suzuki K.
    Urology; 2008 Dec 08; 72(6):1229-33. PubMed ID: 18336887
    [Abstract] [Full Text] [Related]

  • 16. [Expression of PIAS3 an inhibitor of activated STAT3 protein in human prostate cancer].
    Gan L, Yin ZF, Li M.
    Zhonghua Yi Xue Za Zhi; 2008 Feb 05; 88(6):419-21. PubMed ID: 18581899
    [Abstract] [Full Text] [Related]

  • 17. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
    Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS.
    Prostate; 2003 Apr 01; 55(1):71-80. PubMed ID: 12640663
    [Abstract] [Full Text] [Related]

  • 18. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
    Cindolo L, Franco R, Cantile M, Schiavo G, Liguori G, Chiodini P, Salzano L, Autorino R, Di Blasi A, Falsaperla M, Feudale E, Botti G, Gallo A, Cillo C.
    Eur Urol; 2007 Nov 01; 52(5):1365-73. PubMed ID: 17126478
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast growth factor 17 is over-expressed in human prostate cancer.
    Heer R, Douglas D, Mathers ME, Robson CN, Leung HY.
    J Pathol; 2004 Dec 01; 204(5):578-86. PubMed ID: 15538740
    [Abstract] [Full Text] [Related]

  • 20. [Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance].
    Liu BQ, Wu YD, Wei JX, Zhang T, Liu RL, Ma TX.
    Zhonghua Nan Ke Xue; 2007 Nov 01; 13(11):997-1001. PubMed ID: 18077911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.